336 related articles for article (PubMed ID: 26994298)
1. Part II: Biochemical changes after pituitary adenylate cyclase-activating polypeptide-38 infusion in migraine patients.
Guo S; Vollesen AL; Hansen YB; Frandsen E; Andersen MR; Amin FM; Fahrenkrug J; Olesen J; Ashina M
Cephalalgia; 2017 Feb; 37(2):136-147. PubMed ID: 26994298
[TBL] [Abstract][Full Text] [Related]
2. Part I: Pituitary adenylate cyclase-activating polypeptide-38 induced migraine-like attacks in patients with and without familial aggregation of migraine.
Guo S; Vollesen AL; Hansen RD; Esserlind AL; Amin FM; Christensen AF; Olesen J; Ashina M
Cephalalgia; 2017 Feb; 37(2):125-135. PubMed ID: 26994299
[TBL] [Abstract][Full Text] [Related]
3. The role of genetics on migraine induction triggered by CGRP and PACAP38.
Guo S
Dan Med J; 2017 Mar; 64(3):. PubMed ID: 28260603
[TBL] [Abstract][Full Text] [Related]
4. Investigation of the pathophysiological mechanisms of migraine attacks induced by pituitary adenylate cyclase-activating polypeptide-38.
Amin FM; Hougaard A; Schytz HW; Asghar MS; Lundholm E; Parvaiz AI; de Koning PJ; Andersen MR; Larsson HB; Fahrenkrug J; Olesen J; Ashina M
Brain; 2014 Mar; 137(Pt 3):779-94. PubMed ID: 24501094
[TBL] [Abstract][Full Text] [Related]
5. PACAP38 dose-response pilot study in migraine patients.
Vollesen AL; Guo S; Ashina M
Cephalalgia; 2017 Apr; 37(4):391-395. PubMed ID: 27084887
[TBL] [Abstract][Full Text] [Related]
6. Premonitory and nonheadache symptoms induced by CGRP and PACAP38 in patients with migraine.
Guo S; Vollesen ALH; Olesen J; Ashina M
Pain; 2016 Dec; 157(12):2773-2781. PubMed ID: 27842045
[TBL] [Abstract][Full Text] [Related]
7. Effect of the H
Vollesen LH; Guo S; Andersen MR; Ashina M
Cephalalgia; 2019 Apr; 39(5):597-607. PubMed ID: 30165750
[TBL] [Abstract][Full Text] [Related]
8. The effect of pituitary adenylate cyclase-activating peptide-38 and vasoactive intestinal peptide in cluster headache.
Vollesen ALH; Snoer A; Chaudhry B; Petersen AS; Hagedorn A; Hoffmann J; Jensen RH; Ashina M
Cephalalgia; 2020 Nov; 40(13):1474-1488. PubMed ID: 32962406
[TBL] [Abstract][Full Text] [Related]
9. PACAP38 induces migraine-like attacks in patients with migraine without aura.
Schytz HW; Birk S; Wienecke T; Kruuse C; Olesen J; Ashina M
Brain; 2009 Jan; 132(Pt 1):16-25. PubMed ID: 19052139
[TBL] [Abstract][Full Text] [Related]
10. Change in brain network connectivity during PACAP38-induced migraine attacks: A resting-state functional MRI study.
Amin FM; Hougaard A; Magon S; Asghar MS; Ahmad NN; Rostrup E; Sprenger T; Ashina M
Neurology; 2016 Jan; 86(2):180-7. PubMed ID: 26674334
[TBL] [Abstract][Full Text] [Related]
11. Investigation of carbachol and PACAP38 in a human model of migraine.
Schytz HW
Dan Med Bull; 2010 Dec; 57(12):B4223. PubMed ID: 21122466
[TBL] [Abstract][Full Text] [Related]
12. PACAP38 in human models of primary headaches.
Ashina H; Guo S; Vollesen ALH; Ashina M
J Headache Pain; 2017 Nov; 18(1):110. PubMed ID: 29453754
[TBL] [Abstract][Full Text] [Related]
13. The effect of Lu AG09222 on PACAP38- and VIP-induced vasodilation, heart rate increase, and headache in healthy subjects: an interventional, randomized, double-blind, parallel-group, placebo-controlled study.
Rasmussen NB; Deligianni C; Christensen CE; Karlsson WK; Al-Khazali HM; Van de Casteele T; Granhall C; Amin FM; Ashina M
J Headache Pain; 2023 May; 24(1):60. PubMed ID: 37231350
[TBL] [Abstract][Full Text] [Related]
14. PACAP27 induces migraine-like attacks in migraine patients.
Ghanizada H; Al-Karagholi MA; Arngrim N; Olesen J; Ashina M
Cephalalgia; 2020 Jan; 40(1):57-67. PubMed ID: 31299857
[TBL] [Abstract][Full Text] [Related]
15. PACAP38- and VIP-induced cluster headache attacks are not associated with changes of plasma CGRP or markers of mast cell activation.
Pellesi L; Chaudhry BA; Vollesen ALH; Snoer AH; Baumann K; Skov PS; Jensen RH; Ashina M
Cephalalgia; 2022 Jul; 42(8):687-695. PubMed ID: 34822741
[TBL] [Abstract][Full Text] [Related]
16. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.
Akesson L; Ahrén B; Edgren G; Degerman E
Endocrinology; 2005 Feb; 146(2):744-50. PubMed ID: 15514088
[TBL] [Abstract][Full Text] [Related]
17. Early treatment with sumatriptan prevents PACAP38-induced migraine: A randomised clinical trial.
Wienholtz NKF; Christensen CE; Zhang DG; Coskun H; Ghanizada H; Al-Karagholi MA; Hannibal J; Egeberg A; Thyssen JP; Ashina M
Cephalalgia; 2021 May; 41(6):731-748. PubMed ID: 33567890
[TBL] [Abstract][Full Text] [Related]
18. Neuropeptide regulation of interleukin-6 production from the pituitary: stimulation by pituitary adenylate cyclase activating polypeptide and calcitonin gene-related peptide.
Tatsuno I; Somogyvari-Vigh A; Mizuno K; Gottschall PE; Hidaka H; Arimura A
Endocrinology; 1991 Oct; 129(4):1797-804. PubMed ID: 1655384
[TBL] [Abstract][Full Text] [Related]
19. Targeted Pituitary Adenylate Cyclase-Activating Peptide Therapies for Migraine.
Vollesen ALH; Amin FM; Ashina M
Neurotherapeutics; 2018 Apr; 15(2):371-376. PubMed ID: 29464574
[TBL] [Abstract][Full Text] [Related]
20. Pituitary adenylate cyclase activating polypeptide and vasoactive intestinal peptide increase cytosolic free calcium concentration in cultured rat hippocampal neurons.
Tatsuno I; Yada T; Vigh S; Hidaka H; Arimura A
Endocrinology; 1992 Jul; 131(1):73-81. PubMed ID: 1319331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
